Back

Longitudinal validation of the phospholamban (PLN) p.Arg14del risk model

27 August 2022 (12:00 - 12:10)
Organised by:
Congress Presentation Part of: Emerging role of genetic testing for ventricular arrhythmia management Ion Channel Disorders ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Miss Myrthe Van Der Heide

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome
Professor V. Probst (Nantes, FR)
Abstract Slides Video
Presentation thumbnail
Natural History of Patients with Typical and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia
Doctor A. Trancuccio (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Calmodulinopathy is a common cause of critical cardiac phenotypes in fetus and infancy
Doctor M. Fukuyama (Otsu, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of the ICD in patients with catecholaminergic polymorphic ventricular tachycardia
Assistant Professor A. Mazzanti (Pavia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging role of genetic testing for ventricular arrhythmia management

The Event

Event poster

ESC Congress 2022

27 August 2022 12:00 CET
You may be interested in
thumbnail
Congress Session
Risk prediction for ventricular arrhythmias: new tools for improved precision
thumbnail
Congress Presentation
New joint model for the dynamic prediction of heart failure in phospholamban (PLN) p.(Arg14del) positive individuals
thumbnail
Congress Presentation
Time-varying cox model for heart failure prediction in phospholamban p.(Arg14del)-positive individuals

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources